A Randomized Phase 2b Study of Surviving Vaccine Survaxm Plus Adjuvant Temozolomide For Newly-Diagnosed Glioblastoma (SURVIVE)

Research output: Contribution to conference › Presentation

Conference	Neuro-Oncology
Period	9/8/23 → …

Cite this

@conference{2643b03ee7994b66823c5db8218468e5,

title = "A Randomized Phase 2b Study of Surviving Vaccine Survaxm Plus Adjuvant Temozolomide For Newly-Diagnosed Glioblastoma (SURVIVE)",

author = "Manmeet Ahluwalia and Yazmin Odia and Ahmad Ozair and Atulya Khosla",

note = "Neuro-Oncology, Volume 25, Issue Supplement\_2, September 2023, Pages ii52–ii53; Neuro-Oncology ; Conference date: 08-09-2023",

year = "2023",

month = sep,

day = "8",

language = "American English",

}

TY - CONF

T1 - A Randomized Phase 2b Study of Surviving Vaccine Survaxm Plus Adjuvant Temozolomide For Newly-Diagnosed Glioblastoma (SURVIVE)

AU - Ahluwalia, Manmeet

AU - Odia, Yazmin

AU - Ozair, Ahmad

AU - Khosla, Atulya

N1 - Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii52–ii53

PY - 2023/9/8

Y1 - 2023/9/8

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/5036

M3 - Presentation

T2 - Neuro-Oncology

Y2 - 8 September 2023

ER -